Petra Parrag

Ms. Petra Parrag


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RGRenáta Gubán
Renáta Gubán
PPPetra Parrag
Petra Parrag
MKMihály Kispál
Mihály Kispál
KCKata Czirbesz
Kata Czirbesz
TDTímea Danyi
Tímea Danyi
GLGabriella Liszkay Liszkay
Gabriella Liszkay Liszkay
Background/Objectives: Over the past few decades, the incidence of melanoma has been steadily rising. In Hungary, the National Institute of Oncology serves as the national center for the diagnosis and treatment of malignancies, including melanoma. This study aims to analyze our patients’ data, providing a comprehensive characterization of melanoma across the country. Methods: We systematically analyzed the clinico-pathological data of melanoma patients treated in the Department of Oncodermatology between 2001 and 2018. Prognostic parameters were collected from the Hospital Information System of the Institute, including gender, age, tumor location, exulceration of primary lesion, Clark level, and Breslow thickness. In addition, survival analysis was also performed. Results: A total of 6267 melanoma patients were included in the study, with a slight predominance of female cases. The most common tumor location was the trunk. Female patients and younger age groups were more likely to present with lower Breslow thickness, while tumors in the head region were associated with increased thickness. Over the study period, the annual median Breslow thickness showed a significant decline. Female gender, younger age, and lower Breslow thickness was correlated with improved overall survival. Over time, the studied patient population exhibited better outcomes. Conclusions: Despite the rising incidence of melanoma in Hungary, the annual median Breslow thickness in our studied patient group showed a decreasing trend, accompanied by improved mortality outcomes. This highlights the critical role of secondary prevention measures and their effectiveness, as well as the impact of novel therapeutic advancements.